Subscribe To
vaxcyte to host webcast and conference call to discuss results from phase 2 study of its 24-valent pneumococcal conjugate vaccine candidate in adults aged 65 and older and full six-month safety data f
SAN CARLOS, Calif., April 16, 2023 (GLOBE NEWSWIRE) -- vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage v...
April 16, 2023, 5:00 pm
vaxcyte to host webcast and conference call to discuss results from phase 2 study of its 24-valent pneumococcal conjugate vaccine candidate in adults aged 65 and older and full six-month safety data f
SAN CARLOS, Calif., April 16, 2023 (GLOBE NEWSWIRE) -- vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage v...
April 16, 2023, 5:00 pm
vaxcyte to host webcast and conference call to discuss results from phase 2 study of its 24-valent pneumococcal conjugate vaccine candidate in adults aged 65 and older and full six-month safety data f
SAN CARLOS, Calif., April 16, 2023 (GLOBE NEWSWIRE) -- vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage v...
April 16, 2023, 5:00 pm
vaxcyte to host webcast and conference call to discuss results from phase 2 study of its 24-valent pneumococcal conjugate vaccine candidate in adults aged 65 and older and full six-month safety data f
SAN CARLOS, Calif., April 16, 2023 (GLOBE NEWSWIRE) -- vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage v...
April 16, 2023, 5:00 pm
vaxcyte to host webcast and conference call to discuss results from phase 2 study of its 24-valent pneumococcal conjugate vaccine candidate in adults aged 65 and older and full six-month safety data f
SAN CARLOS, Calif., April 16, 2023 (GLOBE NEWSWIRE) -- vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage v...
April 16, 2023, 5:00 pm
vaxcyte to host webcast and conference call to discuss results from phase 2 study of its 24-valent pneumococcal conjugate vaccine candidate in adults aged 65 and older and full six-month safety data f
SAN CARLOS, Calif., April 16, 2023 (GLOBE NEWSWIRE) -- vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage v...
April 16, 2023, 5:00 pm
vaxcyte to host webcast and conference call to discuss results from phase 2 study of its 24-valent pneumococcal conjugate vaccine candidate in adults aged 65 and older and full six-month safety data f
SAN CARLOS, Calif., April 16, 2023 (GLOBE NEWSWIRE) -- vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage v...
April 16, 2023, 5:00 pm
vaxcyte to host webcast and conference call to discuss results from phase 2 study of its 24-valent pneumococcal conjugate vaccine candidate in adults aged 65 and older and full six-month safety data f
SAN CARLOS, Calif., April 16, 2023 (GLOBE NEWSWIRE) -- vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage v...
April 16, 2023, 5:00 pm
vaxcyte to host webcast and conference call to discuss results from phase 2 study of its 24-valent pneumococcal conjugate vaccine candidate in adults aged 65 and older and full six-month safety data f
SAN CARLOS, Calif., April 16, 2023 (GLOBE NEWSWIRE) -- vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage v...
April 16, 2023, 5:00 pm
vaxcyte to host webcast and conference call to discuss results from phase 2 study of its 24-valent pneumococcal conjugate vaccine candidate in adults aged 65 and older and full six-month safety data f
SAN CARLOS, Calif., April 16, 2023 (GLOBE NEWSWIRE) -- vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage v...
April 16, 2023, 5:00 pm
vaxcyte to host webcast and conference call to discuss results from phase 2 study of its 24-valent pneumococcal conjugate vaccine candidate in adults aged 65 and older and full six-month safety data f
SAN CARLOS, Calif., April 16, 2023 (GLOBE NEWSWIRE) -- vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage v...
April 16, 2023, 5:00 pm
vaxcyte to host webcast and conference call to discuss results from phase 2 study of its 24-valent pneumococcal conjugate vaccine candidate in adults aged 65 and older and full six-month safety data f
SAN CARLOS, Calif., April 16, 2023 (GLOBE NEWSWIRE) -- vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage v...
April 16, 2023, 5:00 pm
Sutro biopharma reports full year 2022 financial results, business highlights and select anticipated milestones
– Sutro plans to initiate a Phase 2/3 registration-directed study of luvelta for patients with platinum resistant ovarian cancer in the second quart...
March 30, 2023, 8:30 pm
vaxcyte, inc. (pcvx) q4 2022 earnings call transcript
vaxcyte, Inc. (NASDAQ:PCVX ) Q4 2022 Earnings Conference Call February 27, 2023 4:30 PM ET Company Part...
February 27, 2023, 10:03 pm
vaxcyte to present at the svb securities global biopharma conference
SAN CARLOS, Calif., Feb. 07, 2023 (GLOBE NEWSWIRE) — vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage v...
February 7, 2023, 9:05 pm
vaxcyte has a bright future ahead
Not everything is negative in this bearish market. The healthcare sector is home to stocks with rosy prospects....
November 2, 2022, 3:01 pm
vaxcyte, inc. (pcvx) ceo grant pickering on q4 2021 results - earnings call transcript
vaxcyte, Inc. (PCVX) CEO Grant Pickering on Q4 2021 Results - Earnings Call Transcript...
February 28, 2022, 8:05 pm
vaxcyte, inc. (pcvx) ceo grant pickering on q4 2021 results - earnings call transcript
vaxcyte, Inc. (PCVX) CEO Grant Pickering on Q4 2021 Results - Earnings Call Transcript...
February 28, 2022, 8:05 pm
vaxcyte, inc. (pcvx) ceo grant pickering on q4 2021 results - earnings call transcript
vaxcyte, Inc. (PCVX) CEO Grant Pickering on Q4 2021 Results - Earnings Call Transcript...
February 28, 2022, 8:05 pm